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Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a 
formulation containing microbubble-microdroplet clusters (PS101) together with a regular 
medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue. 
PS101 is confined to the vascular compartment and when the clusters are exposed to 
regular diagnostic imaging US fields, the microdroplets undergo a phase shift to produce 
bubbles with a median diameter of 22 µm. Low frequency, low mechanical index US is 
then applied to drive oscillations of the deposited ACT bubbles to induce biomechanical 
effects that locally enhance extravasation, distribution, and uptake of the coadministered 
drug, significantly increasing its therapeutic efficacy. 
Methods: The therapeutic efficacy of ACT with irinotecan (60 mg/kg i.p.) was investigated 
using three treatment sessions given on day 0, 7, and 14 on subcutaneous human 
colorectal adenocarcinoma xenografts in mice. Treatment was performed with three 
back-to-back PS101+US administrations per session with PS101 doses ranging from 
0.40–2.00 ml PS101/kg body weight (n = 8–15). To induce the phase shift, 45 s of US at 8 
MHz at an MI of 0.30 was applied using a diagnostic US system; low frequency exposure 
consisted of 1 or 5 min at 500 kHz with an MI of 0.20. 
Results: ACT with irinotecan induced a strong, dose dependent increase in the therapeutic 
effect (R2 = 0.95). When compared to irinotecan alone, at the highest dose investigated, 
combination treatment induced a reduction in average normalized tumour volume from 
14.6 (irinotecan), to 5.4 (ACT with irinotecan, p = 0.002) on day 27. Median survival 
increased from 34 days (irinotecan) to 54 (ACT with irinotecan, p = 0.002). Additionally, 
ACT with irinotecan induced an increase in the fraction of complete responders; from 7% 
to 26%. There was no significant difference in the therapeutic efficacy whether the low 
frequency US lasted 1 or 5 min. Furthermore, there was no significant difference between 
the enhancement observed in the efficacy of ACT with irinotecan when PS101+US was 
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InTRODUCTIOn
A prerequisite for successful therapy with a medicinal drug is that 
the active substance reaches its target pathology and that toxicity 
to healthy tissue and nontargeted organs is limited. However, once 
a drug is administrated systemically, the mononuclear phagocyte 
system, the vascular endothelium, the disrupted tumour blood 
flow, the interstitial and osmotic pressure, the tumour stroma, 
endosomal escape, and drug efflux pumps are a few amongst a 
multitude of other biological barriers that severely restrict its 
effective delivery from the vascular compartment into the tissue 
of the targeted pathology (Nizzero et al., 2018). In effect, for a 
number of drugs, the current, passive transvascular delivery 
paradigm is inefficient, and insufficient tumour penetration of 
therapeutic agents to reach effective local concentrations is often 
the outcome. In combination with low therapeutic indexes, 
increasing the dosages is not a viable strategy due to serious and 
widespread adverse effects, generally severely limiting the clinical 
utility of a range of potent drugs.
Whereas lack of sufficient extravasation of drug to the targeted 
pathology is an issue over a range of medicinal therapeutic 
segments, this is predominant in the field of chemotherapy 
for cancer treatment. Regular chemotherapeutics and a range 
of more novel immune therapies induce severe side effects at 
partially effective doses and typically, these medicinal regimes 
are not completed because the cancer is eradicated but because 
the body cannot tolerate more treatment. The outcome is then 
only palliative benefit or life prolongation instead of a cure 
(Hui and Bruera, 2016). For hepatic metastases from colon and 
pancreatic cancer, primary pancreatic cancer and triple negative 
breast cancer treated with standard of care chemotherapy, this is 
unfortunately often the case.
In order to resolve this fundamental problem, over the past 
decades, a wide range of concepts to improve on pathology-
specific uptake (targeted drug delivery) have been explored 
(Devarajan and Jain, 2015). Within oncology, numerous drug 
carrier concepts, e.g., liposomes, micelles, dendrimers, and 
nanoparticles, have been employed either to passively make use 
of the passive enhanced permeability and retention effect (Maeda 
et al., 2000) or in combination with surface ligands to actively 
promote accumulation in tumour tissue through biochemical 
affinity to specifically expressed target groups. While huge 
resources have been spent on finding functional concepts for 
targeted drug delivery over the last two decades, and despite 
promising preclinical results for several of these, there has been 
very limited transition to drug products and clinical practice. 
In truth, the objective remains essentially unresolved in current 
standard of care medicinal therapy.
In recent years, several concepts for ultrasound (US) 
mediated drug delivery have been investigated, some with quite 
encouraging results (Tsutsui et al., 2004; Martin and Dayton, 
2013; Unga and Hashida, 2014). Most of these concepts explore 
the use of commercially available US contrast microbubbles 
injected intravenously. Insonation of the target pathology leads 
to a variety of biomechanical effects that enhance extravasation 
and distribution of drug molecules to target tissue (Kooiman 
et al., 2014; Lentacker et al., 2014). Coinjection of Gemcitabine 
and Sonovue®, with localized US insonation for a hypothesized-
enhanced drug uptake and therapeutic effect during treatment of 
pancreatic cancer (PDAC), has been explored in clinical trials with 
encouraging results (Dimcevski et al., 2016). A similar approach 
is being investigated for treatment of Glioblastoma in humans 
(Carpentier et al., 2016). While these studies have shown great 
promise, there are still several limitations (van Wamel et al., 2016b) 
and Acoustic Cluster Therapy (ACT) has been developed as a new 
therapeutic bubble concept specifically designed to improve on 
the shortcomings of contrast microbubbles for US-targeted drug 
delivery (Sontum et al., 2015; Healey et al., 2016). ACT exploits 
different mechanisms to those induced by contrast microbubbles 
and addresses important deficiencies of the latter. In brief, 
ACT comprises of an intravenous injection of microbubble-
microdroplet cluster dispersion (PS101) coadministration with 
a drug, followed by a two-step, local US insonification for (i) 
activation and (ii) delivery enhancement procedure. US activation 
(at diagnostic US frequencies and MI > 0.10) induces a liquid-to-
gas phase shift of the microdroplet component and the formation 
of large (~22 μm median diameter) bubbles, referred to as ACT 
bubbles. The ACT bubbles are designed to have a size distribution 
that causes them to lodge in the microvasculature of the tissue 
in which the activation occurred, forming transient occlusions in 
these capillaries. The subsequent US enhancement step induces 
controlled volume oscillations of the ACT bubbles that lead 
to enhanced local permeability of the vasculature and other 
localized mechanical effects, allowing for improved extravasation 
of a coinjected drug and its improved distribution into the 
tumour tissue extracellular matrix. The ACT bubbles, being 1,000 
times larger (by volume) than contrast microbubbles, will induce 
orders of magnitude greater biomechanical work. Furthermore, 
being lodged in the vascular compartment until they dissolve, 
the ACT bubbles are in direct contact with a substantial portion 
of the endothelial wall (Sontum et al., 2015) over 5–10 min. This 
also allows for prolonged insonation to induce biomechanical 
effects using low frequency (e.g., 0.5 MHz) low amplitude (MI < 
0.30) US. The concept represents an unprecedented approach to 
US-targeted drug delivery that may improve greatly the efficacy 
of, for example, current chemotherapy regimen.
administered before or after irinotecan. An increase in early dropouts was observed at 
higher PS101 doses. Both mean tumour volume (on day 27) and median survival indicate 
that the PS101 dose response was linear in the range investigated.
Keywords: acoustic cluster therapy, microbubbles, ultrasound, drug delivery, dose/response, irinotecan, 
colorectal cancer
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ACT has been explored in combination with a range of 
drugs for enhancing their efficacy in the treatment of several 
cancer xenograft models in mice, including Abraxane® (nab-
paclitaxel) and paclitaxel for treatment of human prostate cancer 
(Park, 2016; van Wamel et al., 2016b), paclitaxel for treatment of 
human pancreatic ductal carcinoma (PDAC) (Kotopoulis et al., 
2017) and Doxil™ for treatment of triple negative breast cancer 
(companion paper in this journal issue). In these studies, an 
impressive increase in the therapeutic efficacy over drug alone 
is observed when combined with the ACT procedure. To date, 
however, no study using ACT has explored anything other than 
a fixed dose of PS101, the effect of the timing and duration of the 
PS101+US procedure, nor the treatment of colon cancer. In the 
current paper, we evaluate whether PS101+US is able to enhance 
the efficacy of a clinically relevant drug, irinotecan, for treatment 
of human colorectal cancer (CRC) in mice. Furthermore, in 
order to investigate the relationship between PS101 dose and 
therapeutic response, we examine the effect level of a wide range 
of PS101 doses. Finally, the effect of varying the timing and 
duration of the ACT procedure is investigated.
Colorectal cancer is the third most common cancer 
worldwide and approximately 30% of patients with CRC will 
develop liver metastases during the course of their disease. Only 
about 25% of these are amenable to curative-intent treatment 
through metastatectomyand have a 10-year survival rate of 26% 
(Minagawa et al., 2000). For this disease, US-targeted treatment 
of hepatic metastases with ACT has a range of potential 
applications including: as a part of a neo-adjuvant regime prior 
to resection to improve survival outcome, to downstage and 
increase the fraction of patients amenable for curative resection 
and, finally, to improve on survival outcome and palliation for 
nonresectable conditions.
MATeRIAls AnD MeTHODs
Mice and Tumours
SW620 human colon carcinoma cells (American Type Culture 
Collection, Manassas, VA, USA, lot no. 8924081) were grown 
in DMEM containing 10% foetal bovine serum in a humidified 
atmosphere of 5% CO2 at 37°C and passaged before renewal from 
frozen. Cells were regularly screened for mycoplasma by PCR 
using in-house primers.
Human tumour SW620 xenografts were established in 
6-week-old female athymic nude mice, ICR : Ncr-Foxn1 
(nu), bred in-house. Mice were housed in groups of five in 
individually ventilated cages (IVCs) and allowed access to food 
and water ad libitum. All mice were treated in accordance with 
local and national animal welfare guidelines (Workman et al., 
2010). The studies were performed under a UK Home Office 
project license and approved by the Local Animal Welfare & 
Ethical Review Body.
Before tumour implantation, mice were anaesthetised with 
isoflurane; a 100µl tumour cell suspension containing 3x106 
cells was then slowly injected subcutaneously into the left flank 
of the recipient mice. Tumours were allowed to grow for 7–14 
days and treatment started when the tumours were palpable 
and had attained an average volume of 90 ± 3mm3. Prior to 
each treatment anaesthesia was induced by subcutaneous (s.c.) 
injection of Fentanyl citrate: Fluanisone (HypnormVetaPharma 
Ltd, Leeds, UK) and Midazolam (Hypnovel®, Roche Products 
Ltd, Welwyn Garden City, UK) (0.28:10:4.5mg/kg). During 
treatments, the mice were maintained on a mouse handling 
table (Vevo™, Fujifilm Visualsonics Inc., Toronto), and the 
body temperature was controlled thermostatically, with 
vital signs carefully monitored. Following treatments, mice 
were kept in a temperature-controlled recovery chamber 
until fully recovered.
Therapeutics
Clinical grade irinotecan (CPT-11, Seacross Pharmaceuticals 
Ltd, UK) was resuspended in 0.9% saline and administered 
intraperitoneally (i.p.) on days 0, 7, and 14 at a single dose of 
60 mg/kg. The first injection of three PS101 doses was injected 
intravenously (i.v.) approximately 11 min after the irinotecan 
injection, or irinotecan was injected immediately after the last of 
three PS101 injections and US insonation.
As ACT treatments employ an anaesthesia step and such 
are expected to increase animal physical stress (Gargiulo et al., 
2012) resulting in a higher systemic sensitivity to irinotecan, an 
irinotecan doses of 60 mg/kg were chosen; equivalent to 60% 
of the maximum tolerated dose in literature (Motwani et al., 
2001). Literature values show that irinotecan has a maximum 
blood plasma concentration (Cmax) between 0.5 and 1 h after i.p. 
injection, at which time, it is in the range of 6–10µg/ml (Araki 
et al., 1993; Guichard et al., 1998). The irinotecan was cleared to 
less than 1% of Cmax within 24 h.
PS101 (Sontum et al., 2015) was provided by Phoenix Solutions 
AS, (Oslo, Norway). PS101 was prepared by reconstituting 
commercially available microbubbles, Sonazoid™ (GE Healthcare), 
with a microdroplet emulsion of perfluoromethylcylopentane (F2 
Chemicals Ltd., UK) microdroplets. The reconstituted PS101 
formulation consists of a suspension of small microbubble-
microdroplet conjugates (“clusters”) 6 × 107 clusters/ml, 
with a median cluster diameter of 5 µm. The content of 
perfluoromethylcylopentane in PS101 is 6.8 mg/ml. For 
administration of low doses, to allow for acceptable injection 
volumes, PS101 was diluted in 0.9% saline prior to administration.
Apparatus for in Vivo Us Activation and 
Delivery enhancement
The experimental setup (Figure 1) consists of a mouse table 
covered with a 5-mm thick layer of acoustic absorber (Aptflex 
F48™, Precision Acoustics, Dorchester, UK) which reduces 
acoustic reflections from the far side of the animal. An open 
polyethylene water bath mounted above the animal and two 
US transducers for separate agent activation and delivery. US 
activation of PS101 and simultaneous imaging confirmation of 
activation was achieved with a clinical, diagnostic Aplio XG US 
scanner (Toshiba Medical Systems Corporation, Tochigi, Japan) 
combined with a 1204BT linear array to provide simultaneous 
interleaved, nonlinear contrast mode, and fundamental mode 
imaging at 8 MHz (van Wamel et al., 2016a). ACT delivery 
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enhancement was achieved separately using a custom made 500 
kHz, 55 mm active diameter, single element spherically focused 
transducer which had a radius of curvature of 90 mm (Imasonic 
SAS, Voray-sur-l’Ognon, France).
The two transducers were arranged to be interposable on a 
precision sliding arm (Figure 1) mounted above the animal, 
directed at the subcutaneous tumour, insonating through an 
open polyethylene water bag above the animal, with acoustic 
coupling gel between the water bath and the mouse. The tumour 
centre was positioned to sit at the (single) transmit focus of the 
activation transducer and beyond the focus of the enhancement 
transducer (14 cm from its front face). For calculation of delivery 
enhancement MI values, the enhancement field was characterised 
by measuring the spatial and temporal peak-negative pressure a 
priori in situ at the equivalent tumour location in the therapy rig, 
using a calibrated Onda HGL-0200 hydrophone (Onda Corp., 
Sunnyvale, CA). The activation MI values were given as the 
output displayed on the Toshiba Aplio US activation scanner.
The anaesthetised mice were positioned prone on the 
treatment table with their left flank and tumour uppermost. 
For PS101 delivery, a new catheter was made up prior to each 
treatment by combining a winged infusion set, Surflo®, 27G 
butterfly needle (Terumo Europe, Leuven, Belgium), 70-mm 
polyethylene tubing, 0.4-mm internal diameter (Biochrom Ltd, 
Cambridge,UK), and a 27G, 0.5” needle. The catheter primed 
with a 0.9% saline solution was inserted into the lateral tail 
vein of the mouse and patency checked by injecting a small 
volume (<5 µl) of saline solution. The hub of the cannula was 
then filled with 0.9% saline and closed with a cap and taped to 
the animal’s tail with surgical tape, which gave a dead space of 
10 µl to be accounted for in subsequent injection. PS101 was 
drawn into a 1-ml syringe and 60 µl (50 µl effective dose, plus 
10 µl to allow for dead space) was injected intravenously into the 
animal’s lateral tail vein via the preplaced catheter. Following the 
PS101 injection, the tumour was insonated using the 1204BT 
transducer for 45 s at 8 MHz at an MI of 0.30 for activation, then 
the US transducers were transposed and the tumour was further 
insonated for 1 or 5 min (c.f. treatment groups, Table 1) at 500 
kHz (2 cycle excitation, 125 ms burst period) at an MI of 0.20 for 
delivery enhancement by excitation of ACT bubble oscillations. 
FIgURe 1 | Ultrasound (US) administration apparatus and experimental timelines. (Panel A) is a photograph of the activation and delivery enhancement setup 
showing the animal bed with the low frequency transducer in position for delivery enhancement and the clinical transducer to one side which had been transposed 
with the other transducer after the activation step; (Panels B and C) are schematics illustrating the positioning of the activation and delivery enhancement 
transducers, respectively. The water bath and acoustic transmission gel interface permit easy US transducer-to-tumour depth setting and transducer interposition. 
The tail vein catheter and tail are tapped to the imaging table. (Panel D) shows the timelines for the procedures.
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PS101 dosing followed by US activation and enhancement was 
then repeated two more times with the shortest possible time (~2 
min) between the end of an enhancement step and the beginning 
of the next PS101 injection.
Tumour Treatment Regimes
Animals were randomized into eight treatment cohorts of 8 to 15 
mice per group. Two control groups, saline only and irinotecan 
only, received sham US exposure to mimic additional procedure 
induced stress on the animals. The six remaining groups received 
US exposure as described in Apparatus for in-vivo ultrasound 
activation and delivery enhancement section and PS101 at doses 
from 0.4 to 2.0 ml PS101/kg at various timepoints relative to the 
irinotecan injection and with various US enhancement durations 
(Table 1).
Groups 2–7 provided results for the condensed dose-
response study.
liver Toxicity
A liver toxicity study was performed to determine if ACT with or 
without irinotecan induced any sustained liver damage over a 24-h 
period. Table 2 summarizes the treatment groups evaluated. Each 
group consisted of four mice. All mice were healthy and tumour 
free. All groups except the irinotecan groups (Groups 3 and 4 
Table 2) underwent 3 × 45 s activation and 5-min enhancement 
US directed to treat the entire liver. In Groups 7 and 8 (Table 2), 
the irinotecan was injected i.p. a minimum of 10 min before PS101 
injection and US exposure, i.e., mimicking Group 6 from Table 1.
Blood Collection and Processing
Blood samples were collected 1.5 or 24.5 h after the first treatment 
and were collected by terminally anaesthetising the mice using 
isofluraneand performing a cardiac puncture with a 21G needle 
(Becton Dickinson, Franklin Lakes, NJ, USA) and a heparinised 
syringe. A volume of approximately 600 µl was collected from 
each mouse into a 1-ml microcentrifuge tube which had been 
washed with heparin (Eppendorf, Hamburg, Germany). To 
separate the serum, the samples were centrifuged at 3,000 rpm at 
4°C for 15 min and 300 µl of the supernatant was subsequently 
transferred to a 1-ml microcentrifuge tube (Eppendorf). Sampled 
were stored at -20°C until analyzed.
Two liver enzymes, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST), were quantified using a 
UniCelDxC 600 Synchron Clinical System (Beckman Coulter, 
Brea, CA, USA) following the manufactures recommend 
procedures and reagents.
Literature values for the normal range in mice were used to 
minimize the number of animals used. Specifically, the normal 
range for AST and ALT in mice are reported to be in the range of 
300 ± 100 units/L and 100 ± 50 units/L (Oršolić et al., 2010; Gao 
et al., 2014).
Monitoring Therapeutic Response
Animals were monitored daily for body weight and tumour 
size via calliper measurement for 120 days after study start. 
Tumour volumes were calculated using the ellipsoid equation: 
4
3 4 4
3
pi
a b
+



 . Tumour size is reported as fold-increase relative to 
the size on the day of the first treatment. Body weight was used as 
a proxy for toxicity. Tumour growth inhibition (TGI) percentage 
was calculated using the equation: 
V V
V V
c t
c
−( )
−( ) ×0 100 , where Vc and 
Vt are the mean fold increase of the control and treated tumour 
respectively, on day 27. V0 is the control tumour fold growth at 
the start of the treatment, which is always equal to 1.
Following the 3Rs of ethical research and current EU directives 
(Directive 2010/63/EU, 2010), a drug + US-only group was not 
included in the study as the US exposure levels are well below that 
which might cause bioeffects (Miller et al., 2008; Nelson et al., 
2009). Similarly, groups where the treatment was not expected 
TABle 1 | Summary of the treatment groups; number of mice, PS101 dose, PS101+US/irinotecan order, and enhancement ultrasound duration.
group number of 
animals
Treatment Ps101+Us procedure
Drug [i.p.](60 mg/kg) Ps101 Dose [i.v.]
3 x (ml/kg)
Pre-irinotecan or 
Post-irinotecan
enhancement Us duration 
(min)
1 8 Saline – – –
2 15 Irinotecan – – –
3 8 Irinotecan 0.40 Post 5
4 10 Irinotecan 1.03 Post 5
5 8 Irinotecan 1.53 Post 1
6 8 Irinotecan 2.00 Post 5
7 9 Irinotecan 2.00 Post 1
8 9 Irinotecan 2.00 Pre 5
TABle 2 | Summary of the liver toxicity study groups.
group number of 
animals
Treatment (dose) Blood collection 
time (h)
1
4
Sonazoid 
(2.00 ml/kg) + US
1.5
2 24.5
3
Irinotecan (60 mg/kg)
1.5
4 24.5
5
PS101 (2.00 ml/kg) + US
1.5
6 24.5
7 PS101 (2.00 ml/kg) + 
Irinotecan + US
1.5
8 24.5
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to affect tumour growth, based on previous publications and 
literature, were not included and considered outside the scope of 
this study such as PS101 alone and US alone.
As all animals were sacrificed after 120 days to minimize 
the unnecessary burden. Mice that survived 120 days with no 
palpable evidence of tumours and were able to go the three 
weeks of therapy plus 2-week recovery period were considered 
complete responders.
statistical Analysis
Results for average tumour normalized volume are expressed as 
mean ± standard error. Statistical comparisons of mouse weights, 
tumour normalized volume, and liver enzymes were performed 
using an ordinary one-way ANOVA with multiple comparisons 
and a two-stage setup method for controlling the false discovery 
rate, or a student’s t-test where only two groups were compared. 
Survival was compared using a log-rank (Mantel-Cox) test 
between two groups. Mice that were unable to complete the 
3-week treatment plus 2-week recovery period, are reported as 
censored subjects as tick marks in the survival curves. All mice 
are reported in the tumour normalized volume data. Correlation 
was evaluated using a one tailed, nonparametric, Spearman test. 
Complete responders were evaluated using a contingency table 
and a two-sided Fisher’s exact test. A p-value less than or equal 
to 0.05 was considered statistically significant. All statistical 
analyses were performed in Prism 8.1.2 (GraphPad Software Inc, 
San Diego, CA, USA).
ResUlTs
Toxicity
Mean body weight changes as a function of time are shown in 
Figure 2. Irinotecan itself was associated with a body weight 
drop of 5% observed one to two days after each treatment cycle. 
The mice were able to recover to normal body weight by the day 
of each subsequent treatment. In contrast, mice treated with the 
highest PS101 dose (2.00 ml/kg) showed an increase in toxicity 
observed as a 15% drop in body weight one to two days after 
FIgURe 2 | Normalized mouse body weight as a function of time. (Panel A) shows the results for irinotecan alone and ACT with irinotecan for the highest dose of 
PS101 (2.00 ml/kg). Mouse body weight was significantly lower in all the 2.00 ml/kg PS101 groups for the entire 27 days (p = 0.035, ANOVA). (Panel B) pools the 
2.00 ml/kg groups and compares the weight change against all other ACT with irinotecan groups. Increasing the PS101 dose increased the loss in body weight. 
The three grey arrows on the time axis indicate the treatment days. (Panel C) compares the maximum body weight loss to the PS101 dose. The correlation was 
significant (p = 0.0008).
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treatment. When comparing to the irinotecan group alone, this 
weight loss was statistically significant for the entire measured 
period of 27 days (p = 0.035).
The mice treated using ACT with irinotecan (PS101 dose of 
2.00 ml/kg) was not able to return to their normal body weight 
prior to the next treatment cycle. After the three treatment cycles, 
all mice treated using ACT with irinotecan showed progressive 
recovery of body weight and the majority of mice reached their 
starting weight two weeks (the recovery period) after the last 
treatment. The mean body weight of any 2.00 ml/kg PS101 group 
never fell below 20% of the starting weight (Figure 2A).
This transient increased weight loss following ACT treatment 
was observed for all PS101 doses (Figure 2B). At the lowest PS101 
dose (0.4 and 1.03 ml/kg), the difference between ACT with 
irinotecan vs. irinotecan alone was not significant (p > 0.27 and 
0.18 respectively). Overall, increasing the PS101 dose increased 
the mean normalized body weight loss (p < 0.001) (Figure 2C).
Tumour Volumes
Figure 3 shows tumour relative volume as a function of time. 
Irinotecan alone was associated with significant tumour 
inhibition compared to the saline controls, clearly observable in 
Figure 3A (p < 0.0001, day 19, unpaired t-test). Overall, at day 27, 
all ACT with irinotecan groups, except for the lower dose of 0.40 
ml/kg PS101 (p = 0.641) showed significantly inhibited tumour 
growth when compared to irinotecan alone (p = 0.002–0.034).
Figure 3B compares the groups treated using ACT 
with irinotecan at a dose of 2.00 ml/kg PS101. There was 
no difference between the growth curves for 5 and 1 min 
enhancement-US duration (p = 0.904), in the groups where 
PS101 and US were administered post-irinotecan. While 
there was an observable difference between the 5-min 
enhancement-US duration pre-irinotecan group compared to 
both post-irinotecan groups, this difference was not significant 
(p = 0.495 vs. 5 min and 0.555 vs. 1 min). The slight separation 
between the pre-irinotecan and post-irinotecan groups was 
observable approximately 2 days after the second treatment 
(day 9) where the mean tumour volume of the post-groups was 
approximately 0.5-fold larger than the pre-groups. Two days 
after the third treatment (day 16) a slight mean tumour volume 
regression was observed in the pre-irinotecan group only. The 
separation continued throughout the 27-day period. A violin 
plot of all the mice that survived to the end of the treatment 
can be seen in Supplemental Figure 2A.
The normalized tumour volumes of the dose-response 
study in Figure 3C shows the groups that received PS101 and 
enhancement US for 5 min post-irinotecan with various PS101 
doses. In general, increasing the dose of PS101 improved the 
treatment efficacy observed as increased tumour inhibition. 
As previously stated, the 0.4 ml/kg PS101 group showed no 
difference to irinotecan alone. At 1.03 ml/kg PS101, the mean 
tumour volume was 6.1-fold smaller than the irinotecan-alone 
group at day 27 but the difference was barely significant (p = 
0.050). Increasing the PS101 dose to 2.00 ml/kg resulted in a 
tumour inhibition of 8.5-fold vs. irinotecan alone at day 27, i.e., 
less than half the tumour volume, and was statistically significant 
(p = 0.023).
The effect of different PS101 doses when applying enhancement 
US for 1 min can be seen in Figure 3D. In general, there was 
no difference observed between the two doses of 1.53 ml/kg vs. 
2.00 mg/kg PS101. At day 25, a small separation was observed 
between these two groups, but this is a result of a single mouse 
with rapid tumour growth 10 days after the last treatment cycle. 
Hence, only the 2.00 ml/kg group was significantly different from 
irinotecan alone (p = 0.018).
As no significant difference was observed between the 2.00 
ml/kg PS101 groups, independent of the enhancement US 
duration or order of administration in relation to the irinotecan, 
all the mice in these groups were pooled and compared to the 
other PS101 doses in Figure 3E. Here, a clear trend can be seen 
that increasing the PS101 dose resulted in an extended period of 
tumour inhibition post treatment that monotonically increased 
with PS101 dose.
Median Overall survival
Figure 4 shows the effect of ACT with irinotecan in terms of the 
overall survival. Mice not treated with any therapeutic, i.e., just 
saline, had a median survival of 19 days. Treating with irinotecan 
increased median survival to 34 days and was significant (p < 
0.0001). All groups treated using ACT with irinotecan showed an 
increased median survival (Figure 4A).
Figure 4B compares the groups treated using ACT with 
irinotecan at 2.00 ml/kg dose of PS101. There was no significant 
difference between any of the ACT with irinotecan treated 
groups. Comparing to irinotecan alone, only the 1 and 5 min 
post-irinotecan groups were significant, increasing median 
survival from 34 days to 58 and 54 days (p = 0.016 and 0.050), 
respectively.
The survival results from the “dose response” study (Figure 
4C) showed that performing ACT with irinotecan using a 
PS101 dose of 0.40 ml/kg did not significantly improve survival 
(p = 0.295) over irinotecan alone due to early dropouts but did 
increase the median overall survival by 8 days (from 34 to 42 
days). Increasing the PS101 dose to 1.03 ml/kg further increased 
survival rendering it significantly different from that with 
irinotecan alone (p = 0.027) with a median of 41 days. Further 
increasing the PS101 dose to 2.00 ml/kg further improved the 
efficacy of irinotecan resulting in a median survival of 54 days 
(p = 0.050).
Figure 4D compares the survival of the groups that underwent 
enhancement US for one min at two PS101 doses. One minute of 
US enhancement post-irinotecan at a PS101 dose of 1.53 ml/kg 
resulted in a survival increase of 13 days over irinotecan alone, 
from 34 to 47 days. Nevertheless, this result was not significant 
(p = 0.115). Increasing the PS101 dose to 2.00 ml/kg resulted 
in a further improvement in survival to 58 days, rendering it 
significantly better than irinotecan alone (p = 0.016). This was 
the longest survival of all the groups in this study.
Once again, as observed in the tumour volume analysis, there 
was no significant difference in overall survival between all the 
groups treated using ACT with irinotecan at a PS101 dose of 2.00 
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ml/kg, independent of the enhancement-US duration and whether 
PS101+US was administered before or after irinotecan. Hence, the 
data from these groups were pooled and compared with those 
for the other PS101 doses (Figure 4E). Pooling the data resulted 
in a median overall survival of 54 days. There was no significant 
difference between the pooled group and any 2.00 ml/kg group 
(p = 0.980). Comparing the pooled data to irinotecan alone improves 
the significance over irinotecan alone (p = 0.002 vs. p = 0.016).
Complete Responders
All groups except for the saline group showed complete 
responders (Table 3). In the irinotecan-alone group, while all 
FIgURe 3 | Tumour growth as a function of time. Each panel shows a subset of the data to aid comparisons. (Panel A) shows all the groups within this study in a 
single graph. (Panel B) focuses on the groups treated using Acoustic Cluster Therapy (ACT) with irinotecan at 2.00 ml/kg PS101. (Panel C) is a “dose response” 
study and shows the groups treated using ACT with irinotecan where PS101 is administered post irinotecan, with 5 min duration ultrasound (US) at three different 
doses of PS101. (Panel D) compares the efficacy of irinotecan alone vs. ACT with irinotecan where PS101 is administered after irinotecan, with one-minute 
enhancement US at two different PS101 doses. (Panel e) pools all the mice that received 2.00 ml/kg PS101 and compares the data to those for the irinotecan alone 
and other ACT with irinotecan.
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FIgURe 4 | Survival curves of all groups in the study. Each panel shows a subset of the data, each for chosen to allow specific comparisons. The labels on the 
survival curves indicate the groups and the median survival. (Panel A) shows the survival curves of all the groups in the study. Mice that did not complete the full 28 
days of treatment are marked as censored subjects. (Panel B) compares results for various enhancement-US durations and whether PS101+US was administered 
pre-irinotecan or post-irinotecan, for mice that received 2.00 ml/kg PS101. (Panel C) shows the survival curves of the dose response study for groups that received 
ACT with irinotecan with 5-min enhancement US at three doses. (Panel D) shows the survival curves of mice that received PS101 and US post-irinotecan with one 
min of US enhancement at two different PS101doses. (Panel e) pools all the mice that received 2.00 ml/kg PS101 and compares the survival curve to those for the 
other ACT with irinotecan groups and irinotecan alone.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1299
ACT with Irinotecan for CRC TreatmentBush et al.
10
mice were able to complete the treatment and recovery period, 
there was only 1 out of 15 mice (7%) that showed complete 
response. In contrast, all groups treated using ACT with 
irinotecan showed a higher percentage of responders than 
the irinotecan alone group (13%–22% vs. 7%). When pooling 
the 2.00 ml/kg PS101 groups 5 out of 26 mice (19%) showed 
complete response; i.e., more than a tripling of complete 
response. However, the increase in complete responders was not 
significant (p = 0.388).
Dose Response
Figure 5 shows the correlation between ACT with irinotecan at 
various doses vs. median overall survival and tumour volume at 
day 27. In general, an increasing PS101 dose is associated with 
an increased overall survival and a decreased tumour volume at 
day 27. The linear regression of PS101 dose on overall survival 
indicated a slope of 1.46 days/ml/kg of PS101 with a highly 
significant correlation (95% CI = 0.90 to 2.02, R2 = 0.90, p = 
0.005) in addition to the 34 days of survival when treated with 
irinotecan alone (Figure 5A).
A similar beneficial trend was observed for tumour volume 
(Figure 5B). The linear regression of PS101 dose on mean 
normalized tumour volume indicated a slope of -0.68-fold/ml/
kg PS101 with a highly significant correlation (95% CI = -0.86 
to -0.51, R2 = 0.95, p = 0.001). Furthermore, the same trend was 
observed for the TGI percentage where the slope indicated an 
inhibition of 32.27%/ml/kg PS101 (95% CI = 20.19 to 44.36, R2 = 
0.93, p = 0.008, Supplemental Figure 2B).
liver Toxicity
Figure 6 shows the results from the liver toxicity study. In 
general, 1.5 h after the treatment start all groups exhibited 
elevated AST and ALT levels when compared to literature 
normal values. Only the group treated using ACT with 
irinotecan showed a significant difference, indicating there is 
a compounding effect when combining ACT with irinotecan 
(p = 0.0152 – 0.0263 for AST at 1.5 h, p = 0.0004 – < 0.0001 
for ALT at 1.5 h). After 24.5 h the mean levels of both enzymes 
decreased, reaching levels that were not significantly different 
from normal. At this timepoint, the was no significant 
difference between any of the groups.
DIsCUssIOn
The use of ACT with irinotecan for the treatment of CRC showed 
a significant improvement in both TGI and overall survival when 
compare to irinotecan alone. The number of complete responders 
more than doubled when performing ACT with irinotecan vs. 
irinotecan alone. Performing the PS101+US before or after the 
irinotecan injection had no significant effect on the improved 
TABle 3 | Summary of the number of mice that were able to complete the treatment 
plus recovery period, and the number of complete responders for each group.
group Description number completed 
treatment and 
recovery period
number of 
complete 
responders
1 Saline 0 out of 8 (0%) 0 out of 8 (0%)
2 Irinotecan only 15 out of 15 (100%) 1 out of 15 (7%)
3 0.40 ml/kg PS101, 
5 min, post
8 out of 8 (100%) 1 out of 8 (13%)
4 1.03 ml/kg PS101, 
5 min, post
10 out of 10 (100%) 2 out of 10 (20%)
5 1.53 ml/kg PS101, 
1 min, post
7 out of 8 (88%) 1 out of 8 (13%)
6 2.00 ml/kg PS101, 
5 min, post
6 out of 8 (75%) 1 out of 8 (13%)
7 2.00 ml/kg PS101, 
1 min, post
7 out of 9 (78%) 2 out of 9(22%)
8 2.00 ml/kg PS101, 
5 min, pre
6 out of 9 (67%) 2 out of 9(22%)
2.00 ml/kg (pooled) 19 out of 26 (73%) 5 out of 26 (19%)
FIgURe 5 | Median overall survival (Panel A) and tumour volume (Panel B) as a function of the PS101 dose employed when ACT was used to enhance treatment 
with irinotecan. Increasing the PS101 dose was related to both an increased survival and a reduced tumour volume at day 27.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1299
ACT with Irinotecan for CRC TreatmentBush et al.
11
efficacy. In addition, applying US for 1 vs. 5 min also resulted 
in no significant difference. The dose-response study showed 
that in the doses evaluated there was a linear correlation with 
therapeutic efficacy.
Toxicity
On the observed increased level of toxicity (c.f. Figure 2), 
several studies have shown that the gastrointestinal toxicity 
of irinotecan is influenced by the intestinal microbiota and 
inflammation conditions (Brandi et al., 2006; Chityala et al., 
2017). In addition, treatment with microbubbles has been 
shown to induce caecal lesions in murine models (Rasmussen 
et al., 2003) and the development of such is likely to enhance 
the gastrointestinal toxicity of irinotecan. Furthermore, in the 
current study, with tumours inoculated on the flank of the 
animals, collateral US insonation of the intestine was inevitable 
due to the small size of the animal. It is hypothesised that the 
increase in irinotecan toxicity observed in this study is due to 
an increase in inflammatory conditions from the development 
of caecal lesions and/or to an increased concentration of 
irinotecan in the intestine, due to collateral insonation. Hence, 
it is regarded appropriate to have excluded from the survival 
analysis mice that were unable to complete the treatment and 
recovery period. While commercial microbubbles and PS101 
do have different physical properties, and this may influence 
the formation of caecal lesions, it is important to note that a 
large portion of PS101 is indeed a commercial US contrast 
agent; Sonazoid.
In previous studies, which used ACT at similar PS101 doses 
to those employed here but with an experimental configuration 
that shielded the abdomen from the US exposure, no weight 
loss was observed in any of the groups, including an ACT alone 
(i.e., PS101+US) group (van Wamel et al., 2016b). Furthermore, 
extensive toxicity studies have been performed on other species 
and this phenomenon was not observed (Myhre et al., 2016). 
This strongly supports the theory that the weight loss observed 
in this study is due to development of caecal lesions and/or 
collateral insonation of the intestines resulting in enhanced 
off-site delivery of irinotecan, and that this was not a systemic 
toxicity issue.
It should be noted that such effects are very unlikely to translate 
to the clinical application of ACT for enhancing the efficacy 
of irinotecan in the treatment of CRC in humans; collateral 
insonation of the intestine is unlikely in the larger species and the 
development of caecal lesions upon treatment with microbubbles 
is specific to murine species (Dirven et al., 2003).
The liver toxicity study showed that PS101+US did not induce 
any additional toxicity when compared to using the clinical US 
contrast agent Sonazoid™+US. This indicates that there is no 
acute or transient liver toxicity due to the positively charged 
particles in the PS101 formulation. As both the elevated AST 
and ALT levels were transient and dropped close to normal levels 
after 24.5 h, this suggests that the mechanism behind ACT may 
also be transient.
growth Inhibition and survival
As noted from Figures 3 and 4, all groups treated using ACT 
with irinotecan showed a decreased tumour growth rate and 
an increased median survival compared to irinotecan alone. 
At the highest PS101 dose investigated a more than 70% 
reduction in tumour volume was observed vs. drug alone at 
day 27. Also, a more than 70% increase in median survival 
vs. drug alone was observed. Even though not statistically 
significant, the fraction of complete responders in the highest 
PS101 dose groups was 26% vs. 7% for drug alone. The level 
of this enhancement effect is comparable to other studies on 
other disease models treated with different drugs (van Wamel 
et al., 2016b) further indicating the drug- and disease-agnostic 
nature of the ACT concept.
Under the assumptions that the generated ACT bubbles 
have a lifetime of approximately 5 min (van Wamel et al., 
2016a) and that the drug-delivery enhancement provided by 
FIgURe 6 | Aspartate aminotransferase (AST) (Panel A) and alanine aminotransferase (ALT) (Panel B) levels 1.5 and 24.5 h after treatment start. The grey horizontal 
bar shows normal values reported in literature. Only ACT with irinotecan 1.5 h after treatment start shows a significant difference to any other groups. Decreased 
levels were observed for all groups after 24.5 h.
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the biomechanical effects of ACT would be optimal if applied 
when the drug is actually in the vascular compartment, the 
procedures applied in the previous studies have all performed 
the PS101 injection + US procedures after administration of 
drug, at a time that is close to the drug’s maximum plasma 
concentration. Surprisingly, in this study, we observed no 
significant difference between 1 or 5 min of enhancement-US 
insonation, nor between performing the PS101 injection + 
US administration before vs. after administration of drug. 
With regards to the length of US insonation, this finding 
could indicate that the lifetime of the ACT bubbles in the 
present work was shorter than that observed in other studies 
(van Wamel et al., 2016a). Previously, the 5-min lifetime 
observation was made in the absence of low frequency 
enhancement-US insonation, which could be postulated 
to decrease the lifetime. Alternatively, the observation that 
insonating with enhancement US for longer than 1 min 
conveys no additional benefit could mean that all of the 
beneficial effects are induced within the first minute, i.e., they 
saturate after a short period of US insonation and may occur 
partly as a consequence of activation-US insonation as well 
as enhancement-US insonation. This possibility is partially 
consistent with the observations made in van Wamel et al. 
(van Wamel et al., 2016a), which reported a significant and 
substantial improvement of tumour dye-uptake by using ACT 
with 800CW-PEG dye, vs. dye alone, even when insonating for 
45 s with only high-frequency activation-US. Nevertheless, it is 
important to note that the addition of 5 min of enhancement-US 
insonation roughly doubled the enhancement of dye delivery 
in the tumour.
With regards to the sequencing of the procedure, the lack 
of significant difference between the results for the predrug vs. 
postdrug application of PS101+ US procedures demonstrated 
that the drug does not need to be present in the vascular 
compartment at time of PS101+US administration. This 
observation would seem to indicate that PS101+US induces an 
effect on the tumour vasculature and/or interstitial structures 
that persists and allows for enhanced uptake/distribution of drug 
even some time after the procedure. This is also consistent with 
observations made in van Wamel et al (van Wamel et al., 2016a) 
which reports an increase in uptake of a drug surrogate 1 to 2 h 
after the PS101+US procedure. This is further corroborated by 
Åslund et al. (Åslund et al., 2017), which investigated opening 
of the blood brain barrier with ACT and found that its effect on 
uptake of gadodiamide in the brain tissue slowly decreased over 
a period of 72 h, indicating that the microvascular fenestrations 
that the PS101+US procedure may have opened or induced, 
close rather slowly. Both these observations indicate the 
need for further work to fully understand the mechanisms 
involved but importantly also indicate the noncritical nature of 
sequencing and timing, which allows for suitable flexibility in 
clinical applications.
Dose/Response
As indicated from Figure 5, the dose response relation for 
PS101, evaluated both as a function of tumour size at day 27 
and median survival, seems linear over the range investigated, 
with no sign of saturation effects. This would indicate that 
PS101 doses higher than 2.00 ml/kg could lead to even stronger 
enhancement of a drug’s therapeutic benefit. Nevertheless, it 
should be considered whether such high doses would be feasible 
in a clinical regime and how a preclinical murine dose would 
relate to the clinical counterpart.
As the ACT concept is currently in early clinical trials 
at Royal Marsden Hospital (UK), where it is explored for 
treatment of hepatic metastases from CRC and PDAC 
cancers in combination with standard of care chemotherapy 
(FOLFOX/FOLFIRI for CRC origin and nab-paclitaxel plus 
gemcitabine for PDAC origin; ClinicalTrials.gov Identifier: 
NCT04021277), this research provides an important step into 
understanding the importance of both administration order 
and dose.
limitations and Future Work
While this study has shown that ACT with irinotecan can 
improve the therapeutic efficacy when compared to irinotecan 
alone, the mechanism behind this improvement was not 
investigated. While it may be speculated that this improved 
efficacy may be due to increased delivery of the drug to the 
target tissue, this remains to be verified. There are numerous 
other mechanisms that may affect tumour growth which may 
be induced by ACT and may be synergistic with the action of 
the chemotherapeutic agents, such as, changes in intracellular 
signalling (Furusawa et al., 2012; Haugse et al., 2019), 
vasculature (Keravnou et al., 2016; Kotopoulis et al., 2017), 
increased immune response and metabolic activity (Casey 
et al., 2010). These, and other potential mechanisms, should be 
investigated in future work to fully understand the biological 
response to ACT.
COnClUsIOn
ACT can significantly enhance the inhibition of tumour growth 
and increase the overall survival benefit provided by irinotecan 
in a subcutaneous human CRC xenograft. The improved efficacy 
of ACT with irinotecan was shown to increase linearly with the 
dose of PS101 in the range investigated (0.40–2.00 ml/kg) for both 
tumour inhibition and overall survival. There was no significant 
difference in performing ACT before or after the irinotecan 
injection. Furthermore, there was no significant difference 
performing the US enhancement process for 1 or 5 min.
The results from this study indicate the flexibility of ACT, 
which may have implications for its application in the clinic.
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